ArticleCurrent gene therapy2023

SFXN3 is Associated with Poor Clinical Outcomes and Sensitivity to the Hypomethylating Therapy in Non-M3 Acute Myeloid Leukemia Patients.

Yuxuan Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.